Information Registration Programme Overview Satellite Education Programme Virtual Exhibitor Listing


All ePoster presentations will be available to view anytime throughout the Meeting in an Online Library

Search Abstracts by author or title


Conjunctival lymphoma as the initial manifestation of an evolved systemic MALT (mucosa associated lymphoid tissue) lymphoma stage IVb

Poster Details

First Author: R. Wakfie Corieh SPAIN

Co Author(s):    J. San Román Llorens   M. Fernández Gurria   A. Guijarro Alaña   B. García Sandoval   I. Jiménez-Alfaro Morote   N. Alejandre Alba     

Abstract Details


To report a case of conjunctival lymphoma as the first manifestation of a systemic lymphoma.


Department of Ophthalmology. Fundaci�n Jim�nez D�az University Hospital. Madrid, Spain.


Ophthalmological and systemic examination. Histopathology diagnosis and immunohistochemistry of conjunctival tumor and inguinal lymph node. Positron Emission Tomography (PET-CT). Bone marrow aspiration.


A 58-year-old man with no relevant history consulted for redness and discomfort in the left eye, the lesion presented a rapid growth during 1 year in which he lost clinical follow-up. Visual acuity of 1.0 in both eyes. Biomicroscopy revealed a well-defined, salmon-colored conjunctival mass in the temporal sector of the left eye with no limitations or pain in any gaze position. The conjunctival biopsy showed a MALT lymphoma. The evaluation by the hematology department revealed a non-Hodgkin B lymphoma of the marginal zone with a large retroperitoneal mass and infiltration of the bone marrow: a stage IVb tumor.


Conjunctival lymphoma is a rare conjunctival tumor that must be ruled out in the presence of a salmon-pink mass in the conjunctiva without adherence to deep planes. A biopsy of the affected tissue with immunohistochemical studies is essential to confirm the diagnosis and achieve its classification. Immediate referral to oncology-hematology is essential for an adequate extension evaluation, which can reveal a systemic location of the disease, thus allowing its treatment and timely follow-up. Currently the patient has received 6 treatment cycles (Bendamustine-Rituximab) with almost complete reduction of the conjunctival lesion.

Financial Disclosure:


Back to Poster listing